Medigene AG to Discuss Updated Corporate Strategy Call Transcript
Greetings, and welcome to Medigene corporate call. (Operator Instructions) As a reminder, this conference is being recorded. I'd now like to turn the conference over to your host, Dr. Selwyn Ho, CEO. Thank you. Please go ahead, sir.
Today, I'm delighted to share with you an update of Medigene's vision and future plans, which our team have been working on since I joined in late July of this year. Before I start, I would like to point out that I will be making forward-looking statements and point you to our disclosure here.
Medigene is an early-stage platform biotech company focused on developing differentiated, best-in-class T-cell-receptor-engineered T cell or TCR-T therapies for multiple solid tumor indications. We have a proprietary end-to-end platform for developing differentiated TCR-T therapies that consist of both product enhancement technologies, such as our PD1-41BB switch receptor, as well as development optimization technologies, such as our allogeneic-HLA or allo-HLA TCR priming tool.
Our end-to-end
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
